China Resources Pharmaceutical Group Limited’s subsidiary, CR Pharmaceutical Commercial, has finalized the public issuance of the second tranche of its 2026 corporate bonds in mainland China. The offering raised RMB1.40 billion with a three-year tenor and an annual coupon rate of 1.65%.

According to the announcement, net proceeds will be directed toward production expenditures, including working-capital replenishment, repayment of interest-bearing debt and project investment, in accordance with relevant regulations.

The transaction follows the first-tranche issuance disclosed on 27 March 2026, completing the group’s planned onshore financing for the 2026 series.

Shareholders and prospective investors are advised to exercise caution when trading the securities of China Resources Pharmaceutical Group Limited.